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Amyloid hybrid membranes for removal of clinical
and nuclear radioactive wastewater†
Sreenath Bolisetty,‡ab Nastasia M. Coray, ‡a Archana Palika,a
George A. Prenosilc and Raffaele Mezzenga *ad
Nuclear medicine uses various radioactive compounds for the
administration into patients to diagnose and treat diseases, which
generates large amounts of radioactively contaminated water.
Currently, radioactively contaminated hospital wastewater has to
be stored until the contained radionuclides have sufficiently
decayed because cost-effective and efficient removal
technologies are not available. Similar considerations apply in the
nuclear power industry, with, however, decay times of the
radionuclides several orders of magnitude higher. Previously, we
reported hybrid membranes composed of amyloid fibrils
produced from cheap and readily available proteins and activated
carbon, which efficiently removed heavy metal ions and
radioactive compounds from water. Here, we show that these
membranes are highly efficient in the adsorption & removal of
diverse, clinically relevant radioactive compounds from hospital
wastewater by single-step filtration. The radionuclides
technetium (Tc-99m), iodine (I-123) and gallium (Ga-68) can be
removed from water with efficiencies above 99.8% in one single
step. We also demonstrate the purification of a real clinical
wastewater sample from a Swiss hospital containing iodine (I-
131) and lutetium (Lu-177). With the use of single-photon
emission computed tomography (SPECT) and positron emission
tomography (PET), we were able to visualize the accumulation of
the radioactive compounds within the membrane and
demonstrate its outstanding performance. By converting large
volumes of radioactive wastewater into low volumes of solid
radioactive waste, the present technology emerges as a possible
game-changer in the treatment of nuclear wastewater.
1 Introduction
Nuclear medicine comprises the administration of
radioactive substances1 into a patient to treat or visualize
diseases, which are mostly cancer-related.2,3 These
substances are either being used in their elemental form or
they are incorporated into larger molecules.4,5 In a way,
nuclear medicine can be considered as “endoradiology”
because it utilizes radiation emitted from within the patient's
body,6 opposite to radiology, where the patient is being
exposed to radiation sources, coming from outside.
After the administration of nuclear medicine,7 the
radionuclides leave the patient via excretion through their
body fluids. Therefore, until having reached sufficiently low
levels of radioactivity,8,9 all excretions of the patient have to
be collected and treated as radioactive liquid waste.10,11 At
the moment, there is no satisfactory solution to the problem
of radioactive wastewater disposal.12–14 Depending on the
nature of the radionuclides, hospitals rely on on-site storage
of radioactively contaminated liquid waste until radionuclide
decay, after which liquid waste has to be either conditioned
(solidified) or suitably disposed depending on its hazard.
Both processes are very costly. The Swiss Federal Office of
Health calculates 94 000 CHF m−3 only for the conditioning
and interim storage of liquid radioactive waste.15,16 Similar
consideration, but on a much larger scale, apply to the
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Water impact
The use of radionuclides in nuclear medicine and nuclear power
industry generates large amounts of radioactively contaminated
liquids. Currently, radioactive wastewater has to be stored until the
radionuclides have sufficiently decayed. This puts a substantial
logistical and financial burden on many hospitals and nuclear power
plants. This work reports hybrid membranes composed of milk protein
amyloid fibrils and activated carbon which are highly efficient in the
adsorption of radioactive wastewater and allow the conversion of large
volumes of liquid radioactive waste into much smaller volumes of solid
radioactive waste. The technology is scalable, cost-effective, completely
sustainable and highly efficient.
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storage and disposal of liquid radioactive waste in the
nuclear power industry. Rahman et al. clearly described in
their review about the liquid radioactive waste treatment
technologies available for radioactive waste management.16 It
summarizes the application of different conventional
treatment processes (adsorption, ion exchange resins) and
emerging technologies such as continuous
electrodeionization (CEDI) technology and hydrothermal
oxidation method. In both nuclear power plant and clinical
radionuclide wastewater cases, traditional technologies such
as reverse osmosis and nanofiltration cannot be used
efficiently for the purification of radionuclides, as they lead
to a many-fold increase of contaminant concentration in the
residual backwater solution, thus producing lower volumes
of liquid wastewater, which are, however, even more
contaminated, presenting a dramatic threat to public health.
It is still echoing the statement of the Japanese government
announcing that they will have to dump by 2022 to the
Pacific Ocean more than a million tons of radioactively
contaminated water in storage since the Fukushima tragedy
caused by the 2011 tsunami, due to a lack of space in nuclear
radioactive liquid wastewater storage and the inefficiency of
other technologies in handling radioactive liquid waste.17
The must for any remediation technology in radioactive
waste, is to convert large volumes of radioactive liquid
wastewater into much smaller volumes of solid radioactive
waste, which is significantly easier to be stored and disposed.
In 2016, we reported a broadly applicable and highly
efficient filtering system made of amyloid–carbon hybrid
membranes,18 which were made of β-lactoglobulin, the major
component of whey by-product of the dairy industry, and
activated carbon.19 Initial studies have shown filtering
efficacies of three to five orders of magnitude for a broad
spectrum of heavy metal ions as well as for numerous other
compounds including fluoride,20 organic pollutants21 and
bacteria. These adsorption-based depth filter membranes
were also found to be able to remove model radioactive waste
such as uranyl acetate and phosphorus-32.18 Based on the
outstanding performance of these membranes, the absence
of secondary pollutants and notably the affordable and
sustainable nature of the main components, active charcoal
and by-product proteins from the cheese-making process,
this technology is emerging as a game-changer in the broad
water purification field, although the potential in the
remediation of radioactive wastewater contamination
remains to be assessed.
In our earlier reports, we demonstrated the generality of the
approach by studying the filtering efficiency of various hybrid
amyloid fibrils based on egg lysozyme fibrils, bovine serum
albumin, whey protein isolate and β-lactoglobulin fibrils.18
Amyloid fibrils produced from the very inexpensive whey protein
isolate (a by-product of the dairy industry and the industrial
precursor of β-lactoglobulin) showed efficiencies comparable to
those of purified β-lactoglobulin, at a significantly lower cost
related to the waste nature of the original protein source, since
no separation/purification steps are needed using this protein
compared to β-lactoglobulin (obtained by dialysis from whey).
Here we show that hybrid adsorption membranes for efficient
removal efficiency of radionuclides can be produced in a
scalable, easy and cost-effective way by employing whey protein
fibrils instead of β-lactoglobulin.
Here, we demonstrate that amyloid–carbon hybrid
membranes can provide a highly sought solution to the
problem of hospital radioactive wastewater purification and
nuclear wastewater in general. In order to demonstrate the
feasibility of the approach in real context, we use membranes
made not of pure β-lactoglobulin, as in our previous works,
but made using the more affordable low-grade by-product
whey protein. We test the purification performance of
amyloid–carbon hybrid filters for various clinically relevant
radioactive substances with different half-life periods such as
Tc-99m,22–24 I-123,25,26 and Ga-68.27,28 Further real
wastewater obtained from Inselspital in Bern (Switzerland)
containing I-13129 and Lu-17730 was also tested with an
outstanding performance of the membranes. We finally,
assessed the reusability of the membranes, as well as the
scalability of the whey amyloid membranes for large-scale
wastewater treatment, inferring that large-scale use of this
technology on radioactive wastewater treatment is possible.
2 Results and discussion
Fig. 1a shows the schematic representation of the
experimental unit developed to conduct clinical radioactive
material removal using the amyloid hybrid membrane. The
membrane is cropped into a disk of a diameter of 53 mm
(Fig. 1b). The radioactively contaminated water is passed
through the filtration cell by applying gentle pressure with a
syringe (ESI† Fig. S1) with a flow rate of approximately 5 ml
min−1. We used 10 wt% whey hybrid membrane for all testing
protocols. Fig. 1c shows the scanning electron microscope
(SEM) image of the amyloid hybrid membrane surface. The
SEM image clearly shows the cellulose scaffold and the
activated carbon components, while amyloids are revealed
Fig. 1 (a) Schematic diagram of syringe-aided filtration setup. (b)
Cropped filter membrane. (c) SEM image of the membrane surface. (d)
Transmission electron microscope image of the amyloid fibrils. (e)
Schematic representation of the putative binding of radionuclides on
to the amyloid fibrils surface.
Environmental Science: Water Research & TechnologyCommunication
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only at higher magnification, as in the transmission electron
microscope image of Fig. 1d, the amyloid fibrils have contour
lengths of the order of 1 μm or beyond and an average
diameter of 4–6 nm (see ESI† Fig. S2 for AFM images). The
pore distribution in the membrane and additional SEM
images are provided in ESI† Fig. S3 and S4. We assume that
the amyloid fibrils specifically bind and therefore adsorb the
radioactive heavy metal compounds. As will be shown below,
amyloids are the main radionuclide-adsorbing component of
the membranes: Fig. 1e schematically illustrates the
antiparallel cross-beta sheet structure of the amyloid fibrils
and the putative binding sites for the radionuclide ions. The
separation mechanism of heavy metal ions by the amyloid
fibrils has been discussed in detail in our earlier reports.18,31
The basic concept and technology are inspired by the growth
of amyloid plaques in vivo catalyzed by the presence of the
metal ions. Accordingly, also in artificial amyloid membranes
heavy metal ions adsorb very strongly via supramolecular
metal–ligand interactions, providing an outstanding
separation performance. In our earlier reports, we extensively
studied the thermodynamic binding process of metal ions by
amyloid fibrils by performing adsorption isotherms,
isothermal titration calorimetry (ITC)31 and molecular
docking simulations.
2.1 Performance of the amyloid hybrid membrane
Several medicine-relevant radioactive compounds having
various half-life periods such as technetium (Tc-99m), iodine
(I-123), gallium (Ga-68) and the real clinical wastewater
obtained from Inselspital in Bern containing Iodine (I-131)
and Lutetium (Lu-177), were passed through the membrane
to measure the adsorption of these compounds within the
hybrid amyloid membrane. A volume of 20 mL was used in
each experiment. The background-subtracted concentrations
of these radionuclides measured before and after the
filtration using a Wastewater Counter ISOMED 2151 are
reported in Fig. 2. Removal efficiencies (E, %) were calculated
from averaged counts per minute (cpm) measurement values,
and determined using the concentrations in membrane feed
streams (Cf) and permeate (Cp):
E ¼ 1 − Cp
Cf
 
× 100
Removal efficiencies of 99.999% for Tc-99m pertechnetate
(Fig. 2a), 99.999% for I-123 (Fig. 2b) and 99.822% for Ga-68
(Fig. 2c) were achieved with the syringe-aided setup equipped
with a 10 wt% amyloid membrane. Also, even the Swiss
hospital wastewater, when being in a mixture of both Lu-177
and I-131, radionuclides were removed with an efficiency of
99.995% and 99.95%, respectively. As a control, the hybrid
membrane formed by cellulose and carbon (with the same
ratio as in the case of amyloid membranes, but without any
protein) featured, as shown in Fig. 2d (yellow column) Lu-177
removal efficiency of 34.5% and I-131 removal efficiency of
3%. These findings indicate that the adsorption is carried
out primarily by amyloid fibrils and demonstrate a very high
affinity of the amyloid–carbon hybrid membrane for all the
tested radioactive compounds. The radioactivity of the water
after filtration was below the level of detection and thus,
non-radioactive. These results demonstrate clear applicability
of amyloid–carbon hybrid membranes in treating
radioactively contaminated clinical wastewater.
Further, reusability and reproducibility of the results by
membrane filtration were tested by multiple filtration cycles.
Fig. 2 Removal efficiencies for the different radioactive substances.
Aqueous solutions filtrated by amyloid–carbon hybrid membranes
using syringe aided setup for: (a) Tc-99m pertechnetate, (b) I-123, (c)
Ga-68, and (d) hospital wastewater having the mixture of Lu-177 and I-
131.
Fig. 3 Planar scintigraphy of: (a) Tc-99m, (b) I-123 and PET/CT images
of (c) Ga-68 filters after filtration of different volumes of stock
solution, with corresponding gamma counter measurements of the
filtrate in (d)–(f), respectively.
Environmental Science: Water Research & Technology Communication
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After each round of filtration, the membranes were imaged
mainly by an automatic gamma counter (Fig. 3) without any
regeneration step to avoid secondary pollution issues with
radioactive waste. Selected membranes were imaged with
planar scintigraphy, single-photon emission computed
tomography (SPECT) or positron emission tomography (PET)
depending on the respective radionuclide type (cf. Material
and methods in the ESI†).
Tc-99m, I-123, and Ga-68 after multiple cycles of the
filtration are shown in Fig. 3a–c respectively. Planar
scintigraphy imaging in Fig. 3a and b show that with an
increased number of filtration cycles, radioactivity inside the
membrane is increased due to the accumulation of the
adsorbed radionuclide ions with each cycle, compared to the
stock solution. Fig. 3c shows the PET/CT images of Ga-68.
The control stock solution Ga-68 does not show visible colors
in the planar scintigraphy; however radioactive intensity
increases and becomes visible after up-concentrating on the
filter membrane after multiple filtration cycles. Fig. 3d–f
shows that even with multiple cycles of filtrations, the
removal efficiencies still did not decrease. This clearly shows
the membrane was not saturated during these cycles
(Fig. 3b and c). These results are reproducible: testing with
different membrane batches showed identical results.
2.2 Filtration of original radioactive hospital wastewater
In a saturation experiment for real radioactive hospital
wastewater containing a mixture of Lu-177 at 2.79 MBq l−1
and I-131 at 482 kBq l−1 sequentially, samples of 20 ml were
filtered with the hybrid membrane after pre-treatment with a
cellulose filter (Fig. 4). The imaging results and bacterial
removal efficiency are also presented in Fig. 4. Imaging of
membranes used for the syringe aided filtration of the
mixture of Lu-177 and I-131 revealed the accumulation of
radioactive compounds on the corresponding membranes in
correlation with the amount of polluted water that was
filtered by the corresponding membranes (Fig. 4a and b).
Moreover, the membrane was not saturated for any of the
compounds after being subjected to five subsequent cycles of
filtration. While the control hybrid membrane formed by
cellulose and carbon (with the same ratio as in the case of
amyloid membranes, but without any protein) was not able
to remove any of the two compounds (Fig. 4c), both Lu-177
and I-131 were removed successfully by the amyloid–carbon
hybrid membrane: This demonstrates unambiguously that
amyloids are the active components adsorbing radionuclides.
In addition to radionuclides, the tested clinical wastewater
also contained biological pollutants associated with the
physiological cycle. The water before and after the filtration
was thus plated on an LB-agarose gel. Before filtration
(Fig. 4d) bacterial colonies' growth was observed on the
agarose gel after the filtration of the water sample; in
contrast, no biological colony growth is to be observed after
amyloid filtration (Fig. 4e). By exploiting size exclusion, the
hybrid membrane is equally efficient in removing biological
contaminants along with the radioactive radionuclides.
2.3 Scalability of the filtration technology
To test the scalability of this method to remove the clinical
radionuclides, three large membranes having the size of the 20
× 10 cm were tested. A Pulcino® crossflow filter setup was
equipped with three amyloid–carbon hybrid membrane filters
shown in Fig. 5a. After one test-run with water, approximately 4
Fig. 4 (a) Planar scintigraphy of I-313 and (b) Lu-177 filters after filtration
of increasing volumes. (c) Five gamma counter measurements for each
filtrate. Biological contamination in the wastewater: wastewater plated
on LB-agarose gel (d) before and (e) after filtration, respectively.
Fig. 5 (a) Planar scintigraphy of amyloid–carbon hybrid membranes
after filtering of radioactively contaminated water. Filtration of the
aqueous solution of Tc-99m pertechnetate using a Pulcino® crossflow
filter setup equipped with three amyloid–carbon hybrid membrane
filters. (b) Hybrid membranes after filtering radioactively contaminated
water ready for planar scintigraphy. Red arrows indicate the flow path
of the filtrate. (c) Planar scintigraphy of hybrid membranes shows the
accumulation of Tc-99m on the three filter membranes.
Environmental Science: Water Research & TechnologyCommunication
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liters of water (3847.8 g) containing 3 ml of Tc-99m
pertechnetate solution with an activity of 13.71 MBq were
passed through the filter system by gravity flow, i.e. without
external energy supply. The membranes have high mechanical
strength, with a wet bursting strength of 1.5 bar differential
pressure. Samples were taken before and after filtration and
measured for radioactivity. Finally, the filter membranes were
removed from the setup and planar scintigraphy was obtained.
Before filtration, the sample showed an activity of 0.096 MBq.
The sample after filtration resulted in the radioactivity of 0.000
MBq. Scintigraphy of the membranes clearly showed that the
radioactive isotopes were immobilized on the hybrid
membrane (Fig. 5c). Due to radioactivity laboratory regulations,
we were not able to treat very large volumes to identify the
adsorption saturation capacity of the membrane.
Moreover, the scintigraphy showed an intense accumulation
of bound Tc-99m along the flow path of the liquid in the
filtration unit. The inlet and the bottom of the membrane
adsorbed the radioactive Tc-99m, whereas the remaining parts
of the membrane especially the outlet, did not show any signs
of radioactivity. The radioactivity of the water after filtration
was below the level of detection and thus could be considered
as non-radioactive. These findings indicate a very high affinity
of the amyloid–carbon hybrid membrane of the tested
compound Tc-99m pertechnetate and demonstrate that this
method is easily scalable for large scale wastewater treatment.
3 Conclusions
In summary, we have demonstrated that amyloid–carbon
hybrid membranes are capable of removing clinically relevant
radioactive substances from hospital wastewater by
adsorption mechanism. The approach presented here is
scalable, sustainable and of very low cost in that it relies on
very affordable raw materials. Importantly, the membranes
have proven to bear the potential to be used for the
purification of radioactive wastewater on a large scale. For
example, while the metastable Tc-99m tested here, is a short-
lived (half-life about 6 hours) nuclear isotope used in nuclear
medicine produced from molybdenum-99, long-lived
technetium isotopes, notably Tc-99, with a half-life of over
210 000 years, are contributing components of nuclear reactor
effluents, which must be controlled and for which liquid
storage is unthinkable. Since the metal–ligand binding
characteristics between radionuclides and amyloids are fully
independent on the nuclear details of the isotopes, it can
safely be stated that any technetium isotopes will be removed
with outstanding efficiency by this technology. Similar
considerations apply to the release of the long-lived I-129.
Other long-lived fission products, such as Zr-93 remain to be
evaluated, but our results for the nuclides considered point
to a universal approach in radioactive wastewater treatment
and warrant further investigation into filtration systems for
liquid nuclear waste and nuclear energy incidents
remediation. The possibility of converting large volumes of
radioactive liquid waste into low volumes of solid radioactive
waste is a key requirement in the nuclear and clinical
radioactive wastewater treatment. The authors plan to
conduct future studies at pilot scale level in other Swiss
hospitals to assess the long-term performance of the
technology with additional clinically relevant radioactive
wastewater compounds, the adsorption capacity, as well as
the economic and sustainability footprint of this technology
on radioactive waste. Our vision is to extend these studies to
further relevant radionuclides used in nuclear medicine and
nuclear industry and to pave the way to an efficiently and
sustainable radioactive wastewater management.
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